NovaBay Pharmaceuticals Engages Leading Chinese Marketing Firm to Drive Consumer Sales of DERMAdoctor Skincare Products in China
23 February 2022 - 10:50PM
Business Wire
New marketing partner to provide omnichannel
integrated marketing and branding services including managing
DERMAdoctor’s flagship retail store on Tmall.com, the leading B2C
online retailer in China
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company
developing and commercializing high-quality, scientifically
formulated eyecare and skincare products, announces the engagement
of one of China’s leading marketing firms for omnichannel
integrated marketing and branding services of DERMAdoctor skincare
products in China. NovaBay’s new marketing partner will also manage
DERMAdoctor’s online flagship store on Tmall.com, the leading
business-to-consumer (B2C) online retailer in China.
“As purchasing power and digitalization have increased across
China, e-commerce has grown exponentially. Many of the world’s
leading brands have entrusted our new marketing partner to bring
their products to the vast Chinese market, and we are delighted to
engage them to drive sales of our DERMAdoctor product line,” said
Justin Hall, NovaBay CEO. “Over the years NovaBay has developed
strong relationships in China and we know that success there is
predicated on a strong, local business partner with word-of-mouth
as one of the best ways to attract new customers. Our new marketing
partner brings us a greatly expanded network of bloggers and
influencers together with strong social media capabilities, making
it an optimal choice for creating positive brand awareness and
promoting sales of DERMAdoctor products.”
NovaBay’s newly engaged Chinese marketing firm will utilize its
extensive market knowledge to develop a customized marketing plan
for DERMAdoctor products built around functional skincare and the
concepts of healthy skin and natural ingredients. The marketing and
branding strategy will include social engagement with key opinion
leaders to create brand awareness with messaging tailored to target
audiences. Additionally, the marketing partner will expand the
currently promoted DERMAdoctor KP Duty products to include the full
KP Duty line of exfoliating body treatments, as well as the full
Kakadu C product line of vitamin C-based elixirs with anti-aging
properties.
The management of the DERMAdoctor flagship retail store on
Tmall.com will be assumed by NovaBay’s newly engaged marketing
partner beginning on March 1, 2022. Tmall.com accounted for more
than 60% of B2C online retail transactions in China in 2020.
According to Euromonitor, the market for functional skincare
products in China is expected to exceed $100 billion by 2024 and to
account for more than 22% of the total Chinese skincare market.
About NovaBay Pharmaceuticals, Inc:
NovaBay Pharmaceuticals, Inc. is a pharmaceutical company that
develops and sells scientifically created and clinically proven
consumer products for the eyecare and skincare markets. Avenova® is
the most prescribed antimicrobial lid and lash spray and CelleRx®
is a breakthrough product in the beauty category. In November 2021,
NovaBay acquired DERMAdoctor, LLC, a company offering more than 30
dermatologist-developed skincare products sold through traditional
domestic retailers, digital beauty channels and international
distributors.
NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release may be forward looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial
progress and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding our business
strategies, current product offerings, marketing efforts, and any
future revenue that may result from selling such products, as well
as generally the Company’s expected future financial results. These
statements involve known and unknown risks, uncertainties and other
factors that may cause actual results or achievements to be
materially different and adverse from those expressed in or implied
by the forward-looking statements. Factors that might cause or
contribute to such differences include, but are not limited to,
risks and uncertainties relating to the size of the potential
market for our products, the integration of DERMAdoctor’s business
into the Company’s business, the possibility that the available
market for the Company’s products will not be as large as expected,
the Company’s products will not be able to penetrate one or more
targeted markets, and revenues will not be sufficient to meet the
Company’s cash needs. Other risks relating to NovaBay’s business,
including risks that could cause results to differ materially from
those projected in the forward-looking statements in this press
release, are detailed in NovaBay’s latest Form 10-Q/K filings and
Registration Statement on Form S-1 filing with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay Informed on
NovaBay’s Progress
Like us on Facebook Follow us on Twitter Connect with NovaBay on
LinkedIn Visit NovaBay’s Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com Avenova.com
DERMAdoctor Purchasing Information
For DERMAdoctor purchasing information: Please call 877-337-6237 or
email service@dermadoctor.com DERMAdoctor.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220223005019/en/
NovaBay Contact Justin Hall
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2024 to May 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From May 2023 to May 2024